Chosa Oncology (CHOSA) Q1 2025 earnings summary

Executive summary

• Advanced precision oncology with DRP® biomarker platform, expanding predictive capabilities to both cisplatin and carboplatin therapies for multiple cancer types, including lung and breast cancer.

• Initiated a retrospective, blinded lung cancer study with SPLENDOUR data and leading oncology experts; initial results expected end of Q2 2025.

• Presented significant results in breast cancer, showing DRP® can identify responders to carboplatin, broadening market potential.

• Focused on regulatory progress, commercial partnerships, and presence at major oncology conferences.

Financial highlights

• Other operating income for Q1 2025 was 2 TSEK (0 TSEK in Q1 2024).

• Net loss after financial items was -1,807 TSEK (compared to -1,477 TSEK in Q1 2024).

• Earnings per share were -0.025 SEK (-0.023 SEK in Q1 2024).

• Cash and cash equivalents at March 31, 2025, totaled 3,402 TSEK (7,749 TSEK at March 31, 2024).

• Equity at period end was 11,628 TSEK (16,425 TSEK at March 31, 2024), with a balance sheet total of 12,976 TSEK (18,544 TSEK at March 31, 2024).

Outlook and guidance

• Initial results from the lung cancer SPLENDOUR study expected by end of Q2 2025.

• Expansion of DRP® to predict carboplatin response in breast cancer, with further validation planned.

• Continued focus on regulatory processes and commercial partnerships.